Format

Send to

Choose Destination
Indian J Hematol Blood Transfus. 2014 Sep;30(Suppl 1):202-4. doi: 10.1007/s12288-013-0327-3. Epub 2014 Feb 9.

Autologous immune enhancement therapy in Philadelphia chromosome positive acute lymphoblastic leukemia.

Author information

1
Pediatric Hematology, Oncology and Marrow Transplantation Unit, Apollo Speciality Hospitals, Chennai, India.
2
Nichi-In Centre for Regenerative Medicine, PB 2278, Chennai, 600026 India.
3
Faculty of Medicine, Yamanashi University, Chuo, 409-3898 Japan.
4
Biotherapy Institute of Japan, Tokyo, 135-0051 Japan.

Abstract

Advances in current treatment regimens in childhood acute lymphoblastic leukemia (ALL) have resulted in cure rates of 75-80 %. Some molecular genetic abnormalities confer a poor prognosis. Of these, the chromosomal translocation t (9;22)-Philadelphia chromosome is associated with the worst outcome in childhood ALL. Optimal therapy for this variant of ALL includes chemotherapy as per high risk schedule, imatinib and early stem cell transplantation. We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center